Tag Archives: GLP-1

November, 2016

22 November
Novo Nordisk’s Diabetes Drug Xultophy Wins FDA Approval

PLAINSBORO, N.J., Nov. 21, 2016 /PRNewswire/ — Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration (FDA) approved the New Drug Application for Xultophy®100/3.6 (insulin degludec 100 units/mL and liraglutide 3.6 mg/mL injection). Xultophy® 100/3.6 is a once-daily, combination of Tresiba® (insulin degludec …
Share

28 July
Sanofi’s Adlyxin Receives FDA Approval for Treatment of Type 2 Diabetes

PARIS, July 27, 2016 /PRNewswire/ — Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved Adlyxin™ (lixisenatide), a once-daily mealtime GLP-1 receptor agonist injection indicated as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes. “The approval of Adlyxin reaffirms our …
Share

25 April
Heptares Scientists Solve Structures of GLP-1 and Glucagon Receptors Enabling Structure-Based Design for Metabolic Disease

Heptares Therapeutics (“Heptares”), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), announces that its scientists have solved the high-resolution X-ray crystal structures of the GLP-1 (glucagon-like peptide 1) and glucagon receptors. Both receptors play important roles in the management of blood glucose levels and are considered to …
Share